Gliadel (Carmustine)

Brand Name

Gliadel

Generic Name

Carmustine

View Brand Information

FDA approval date: December 13, 2012

Classification: Alkylating Drug

Form: Kit, Wafer

What is Gliadel (Carmustine)?

Carmustine for injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. Carmustine for injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors Multiple myeloma-in combination with prednisone Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)

Who is this study for: Patients with Multiple Sclerosis

Enrollment Status: Recruiting

Publish Date: October 01, 2025

Intervention Type: Procedure, Biological

Study Drug: Best Available Therapy (BAT)

Study Phase: Phase 3

Summary: This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be...

A Prospective, Multicenter, Open-Label Clinical Study of Orelabrutinib in Combination With Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in Treatment-Naive, Non-High-Risk Mantle Cell Lymphoma (MCL)

Enrollment Status: Recruiting

Publish Date: September 30, 2025

Intervention Type: Drug

Study Phase: Phase 2

Summary: This multicenter, open-label, trial aims to evaluate the efficacy and safety of orelabrutinib in combination with rituximab with optional autologous hematopoietic stem cell transplantation in patients with non-high-risk mantle cell lymphoma (MCL). The primary objective is to assess the optimal complete response (CR) rate during the induction phase, with secondary objectives including progression-f...

SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

Who is this study for: Adult patients with Pancreatic Adenocarcinoma

Enrollment Status: Recruiting

Publish Date: August 22, 2025

Intervention Type: Drug, Device

Study Drugs: Melphalan, Vitamin B12b, Vitamin C, Ethanol, Carmustine, Autologous Hematopoietic Stem Cells

Study Phase: Phase 1

Summary: The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in associat...

View All Clinical Trials

Related Latest Advances

From ethanol to propylene glycol: A safer future for carmustine.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: October 16, 2025

Analysis of Anticancer Drugs Used to Treat Brain Cancer Using the Cheapest and Costliest Drugs in India: A Cost-comparison Health Economics Study.

Journal: The Journal of the Association of Physicians of India

Published: October 16, 2025

Ex Vivo and In Vivo Evaluation of an In Situ Nanogel Composite loaded with Carmustine: Implications for efficient nose-to-brain delivery.

Journal: Pharmaceutical development and technology

Published: September 23, 2025

View All Latest Advances

Brand Information

Gliadel (carmustine)

1INDICATIONS AND USAGE

GLIADEL Wafer is indicated for the treatment of patients with:

newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and
recurrent glioblastoma as an adjunct to surgery.

2DOSAGE FORMS AND STRENGTHS

GLIADEL Wafer is an off-white to pale yellow round wafer. Each GLIADEL Wafer contains 7.7 mg of carmustine.

3CONTRAINDICATIONS

None.

4ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

Seizures
Intracranial Hypertension
Impaired Neurosurgical Wound Healing
Meningitis

4.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

5DESCRIPTION

GLIADEL Wafer is an implant for intracranial use, containing carmustine, a nitrosourea alkylating agent, and polifeprosan, a biodegradable copolymer used to control the release of carmustine. It is a sterile, off-white to pale yellow wafer approximately 1.45 cm in diameter and 1 mm thick. Each wafer contains 7.7 mg of carmustine [1, 3-bis (2-chloroethyl)-1-nitrosourea, or BCNU] and 192.3 mg of a biodegradable polyanhydride copolymer. The copolymer, polifeprosan 20, consists of poly [bis (p-carboxyphenoxy)] propane and sebacic acid in a 20:80 molar ratio. Carmustine is homogeneously distributed in the copolymer matrix.

The structural formula for polifeprosan 20 is:

The structural formula for carmustine is:

6REFERENCES

"OSHA Hazardous Drugs".

7HOW SUPPLIED/STORAGE AND HANDLING

GLIADEL Wafer is supplied in a single dose treatment box containing eight individually pouched wafers. Each wafer contains 7.7 mg of carmustine and is packaged in two aluminum foil laminate pouches. The inner pouch is sterile and is designed to maintain product sterility and protect the product from moisture. The outer pouch is a peelable overwrap. The outside surface of the outer pouch is not sterile.

NDC for single dose treatment box: 24338-050-08

8PRINCIPAL DISPLAY PANEL - 8 Wafer Box

NDC 24338-050-08

GLIADEL
(carmustine implant)

7.7 mg carmustine/wafer

For intracranial use.

Each sterile wafer contains

Contents:

Store at or below -20°C (-4°F).
Rx only

Warning:Cytotoxic agent
See package insert for full prescribing information.
Keep out of the reach of children.

Azurity PHARMACEUTICALS, Inc.